Experimental Drug Panobinostat Shows Little Activity In MDS Patients, Sarah Cannon Research Institute Study

MDS Beacon -- Preliminary results of a Phase 2 trial show that the experimental drug panobinostat has little activity in patients with relapsed and resistant myelodysplastic syndromes.

MORE ON THIS TOPIC